Loading
Sharp Therapeutics Corp. Stock: price and insider trades · Canada
CA·Mcap CA$41.2M
Sharp Therapeutics Corp.: what insiders have been doing
We have very little insider data for Sharp Therapeutics Corp. so far: the most recent filing dates from 7 August 2026. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$1.37
Analyst consensus
Income statement
EBITDA-CA$5.9M
Net income-CA$6.2M0.0% margin
Valuation
Beta-1.15
Balance sheet & cash
Market capCA$41.2M
Total debtCA$1.3M
Free Cash Flow-CA$4.8M
Profitability & ownership
ROE-3762.2%
ROA-131.6%
% insiders42.5%
% institutions0.0%
Last declaration on 7 August 2026
Declarations1 total
307,693 shares@ CA$0.910.0095% mcap100.0% of flowCommon SharesTSXSEDI:4760528
1 of 1 declaration
About Sharp Therapeutics Corp.
Sharp Therapeutics Corp. is a company focused on developing innovative therapeutic solutions. It is listed on the XTSE market.
